Skip to main content

Table 3 Hazard Ratios for HF According to MAFLD Status, and by age

From: Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study

 

Case/Participants

Incidence (/1, 000 person years)

HR (95%CI)

Model 1

Model 2

Model 3

Age group

     

age < 45 years

     

Non-MAFLD

108/20,974

0.37(0.31,0.45)

reference

reference

reference

MAFLD

97/7574

0.93(0.77,1.40)

1.98(1.50,2.62)

1.99(1.51,2.63)

1.82(1.37,2.42)

45 ≤ age < 65 years

     

Non-MAFLD

950/36,247

1.97(1.85,2.10)

reference

reference

reference

MAFLD

789/18,734

3.20(2.98,3.43)

1.63(1.48,1.80)

1.65(1.50,1.81)

1.50(1.36,1.65)

age ≤ 65 years

     

Non-MAFLD

887/10,709

7.54(7.06,8.05)

reference

reference

reference

MAFLD

429/4447

8.80(8.00,9.67)

1.19(1.06,1.34)

1.20(1.07,1.35)

1.13(1.01,1.28)

Sensitivity 1*

     

Non-MAFLD

1811/67,796

2.04(1.95,2.13)

reference

reference

reference

MAFLD

1216/30,656

3.05(2.88,3.23)

1.50(1.39,1.61)

1.51(1.40,1.62)

1.39(1.29,1.49)

Sensitivity 2*

     

Non-MAFLD

1768/67,753

1.99(1.90,2.08)

reference

reference

reference

MAFLD

1202/30,642

3.01(2.84,3.18)

1.51(1.41,1.63)

1.53(1.42,1.64)

1.41(1.31,1.52)

  1. * Sensitivity 1: excluding 233, myocardial infarction occurred during follow-up
  2. Sensitivity 2: excluding 290, heart failure developed within two years
  3. Model 1: adjusted for age, gender;
  4. Model 2: adjusted for all the variables in model 1 and Smoking, Drinking, Education level, Salt status and Physical activity;
  5. Model 3: adjusted for all the variables in model 2 and Antihypertensive treatment, Antidiabetic treatment and Lipid-lowering treatment
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us